Suppr超能文献

吗多明对急性心肌梗死患者外周循环及心脏血流动力学的减负作用。

Unloading effects of molsidomine on peripheral circulation and cardiac hemodynamics in patients with acute myocardial infarction.

作者信息

Seino Y, Vyden J K, Rose H B, Takano T, Obayashi K, Hayakawa H, Kimura E

出版信息

Angiology. 1983 Aug;34(8):535-45. doi: 10.1177/000331978303400805.

Abstract

The unloading mechanisms and side of peripheral action of the new antianginal drug molsidomine was compared with isosorbide dinitrate (ISDN) in 14 patients with acute myocardial infarction using a Swan-Ganz catheter and venous occlusion plethysmography. Sublingual molsidomine (2-4 mg) increased calf venous capacitance (CVC) (0.42 +/- 0.18 to 0.64 +/- 0.09 ml/100 ml, p less than 0.05) from 30 to 240 minutes, while simultaneously lowering of PCWP (25.9 +/- 4.9 to 15.8 +/- 7.3 mmHg, p less than 0.05) and CVP (9.3 +/- 3.7 to 5.8 +/- 3.5 cmH2O, p less than 0.05). Calf blood flow (CBF), calf vascular resistance (CVR), CI, TSPR and SWI were not affected significantly. Molsidomine reduced preload more than 240 minutes after its administration. Sublingual ISDN increased CBF into the initial 15 minutes (1.19 +/- 0.49 to 1.83 +/- 0.98 ml/100ml/min, p less than 0.05) and CVC from 5 to 60 minutes (0.42 +/- 0.19 to 0.68 +/- 0.24 ml/100ml p less than 0.01) while simultaneously lowering PCWP (24.3 +/- 2.2 to 14.6 +/- 4.5 mmHg, p less than 0.01) and CVP (9.0 +/- 2.8 to 5.5 +/- 3.5 cmH2O, p less than 0.05). Neither drug affected cardiac index, blood pressure or systemic vascular resistance. These data suggest that molsidomine significantly lowered elevated preload (PCWP/PCP) by dilating venous capacitance vessels. Its length of action was 240 minutes compared with 60 minutes obtained with ISDN, which suggests this new agent may be of marked benefit in the AMI patients suffering from backward failure uncomplicated by forward failure in whom continued preload reduction is necessary. (Results are expressed as the mean +/- standard deviation).

摘要

在14例急性心肌梗死患者中,使用Swan - Ganz导管和静脉阻塞体积描记法,将新型抗心绞痛药物莫索尼定的卸载机制和外周作用部位与硝酸异山梨酯(ISDN)进行了比较。舌下含服莫索尼定(2 - 4毫克)在30至240分钟内增加了小腿静脉容量(CVC)(从0.42±0.18增至0.64±0.09毫升/100毫升,p < 0.05),同时降低了肺毛细血管楔压(PCWP)(从25.9±4.9降至15.8±7.3毫米汞柱,p < 0.05)和中心静脉压(CVP)(从9.3±3.7降至5.8±3.5厘米水柱,p < 0.05)。小腿血流量(CBF)、小腿血管阻力(CVR)、心脏指数(CI)、总外周血管阻力(TSPR)和每搏功指数(SWI)未受到显著影响。莫索尼定在给药后240分钟以上降低前负荷的作用更明显。舌下含服ISDN在最初15分钟内增加了CBF(从1.19±0.49增至1.83±0.98毫升/100毫升/分钟,p < 0.05),在5至60分钟内增加了CVC(从0.42±0.19增至0.68±0.24毫升/100毫升,p < 0.01),同时降低了PCWP(从24.3±2.2降至14.6±4.5毫米汞柱,p < 0.01)和CVP(从9.0±2.8降至5.5±3.5厘米水柱,p < 0.05)。两种药物均未影响心脏指数、血压或全身血管阻力。这些数据表明,莫索尼定通过扩张静脉容量血管显著降低了升高的前负荷(PCWP/PCP)。其作用时长为240分钟,而ISDN为60分钟,这表明这种新药对于患有单纯后向衰竭且无需前向衰竭的急性心肌梗死患者可能具有显著益处,因为这类患者需要持续降低前负荷。(结果以平均值±标准差表示)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验